読み込み中
Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending symptomatic, full-thickness cartilage damage in the knee, and Epicel, a permanent skin replacement designated as a humanitarian use device for treating deep-dermal or full-thickness burns in both adults and children. Additionally, Vericel is progressing NexoBrid, an orphan biological product currently in the registration phase, which aims to remove eschar from deep partial-thickness or full-thickness thermal burns in adults. Established in 1989 under its former name, Aastrom Biosciences, Inc., the company is headquartered in Cambridge, Massachusetts.
前日終値
$40.10
+$0.05 · +0.12%
日中の時刻はETです。市場データは遅延する場合があります。
Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending symptomatic, full-thickness cartilage damage in the knee, and Epicel, a permanent skin replacement designated as a humanitarian use device for treating deep-dermal or full-thickness burns in both adults and children. Additionally, Vericel is progressing NexoBrid, an orphan biological product currently in the registration phase, which aims to remove eschar from deep partial-thickness or full-thickness thermal burns in adults. Established in 1989 under its former name, Aastrom Biosciences, Inc., the company is headquartered in Cambridge, Massachusetts.
日中レンジ
現在 $40.10
52週レンジ
現在 $40.10
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
62
割安
センチメント
66
強気
リスク
33
中程度のリスク
モメンタム
67
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending symptomatic, full-thickness cartilage damage in the knee, and Epicel, a permanent skin replacement designated as a humanitarian use device for treating deep-dermal or full-thickness burns in both adults and children. Additionally, Vericel is progressing NexoBrid, an orphan biological product currently in the registration phase, which aims to remove eschar from deep partial-thickness or full-thickness thermal burns in adults. Established in 1989 under its former name, Aastrom Biosciences, Inc., the company is headquartered in Cambridge, Massachusetts.
日中レンジ
現在 $40.10
52週レンジ
現在 $40.10
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 2.76億 USD | 2.37億 USD | 1.98億 USD | 1.64億 USD | 1.56億 USD |
| 売上原価 | 7066万 USD | 6511.7万 USD | 6194万 USD | 5457.7万 USD | 5015.9万 USD |
| 粗利益 | 2.06億 USD | 1.72億 USD | 1.36億 USD | 1.1億 USD | 1.06億 USD |
| 研究開発 | 2756.3万 USD | 2479.7万 USD | 2104.2万 USD | 1994.3万 USD | 1628.7万 USD |
| 販売・一般管理 | 1.67億 USD | 1.43億 USD | 1.21億 USD | 1.07億 USD | 9759.2万 USD |
| 営業費用 | 1.95億 USD | 1.68億 USD | 1.42億 USD | 1.27億 USD | 1.14億 USD |
| 受取利息 | 700.7万 USD | 641万 USD | 463.2万 USD | 134.1万 USD | 22.4万 USD |
| 支払利息 | 155.6万 USD | 61.4万 USD | 60万 USD | 36.6万 USD | 4000 USD |
| 減価償却費と償却費 | 1136.1万 USD | 550.4万 USD | 463.2万 USD | 398.1万 USD | 296.5万 USD |
| 営業利益 | 1104.4万 USD | 451.9万 USD | −646.4万 USD | −1705.8万 USD | −785.4万 USD |
| 純利益 | 1651.8万 USD | 1036.2万 USD | −318.2万 USD | −1670.9万 USD | −747.1万 USD |
会社概要が更新されました 2026年10月10日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$61.33
上昇余地（52.94%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI6473.24万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM5408.58万0.07%782.66億 USD0.19%$278.94+0.49%
State Street SPDR S&P Biotech ETFXBI4479.1万0.45%98.74億 USD0.35%$153.77+3.00%
Vanguard Extended Market ETFVXF2370.91万0.02%954億 USD0.05%$235+0.80%
iShares Russell 2000 Growth ETFIWO1909.75万0.14%139.72億 USD0.24%$356.78+0.94%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM1886.23万0.12%158.4億 USD0.03%$53.45+0.17%
iShares Biotechnology ETFIBB1570.48万0.15%102.79億 USD0.44%$206.49+3.00%
Dimensional - US Small Cap ETFDFAS1482.23万0.04%338.69億 USD0.31%$78.35+0.32%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOState Street SPDR Portfolio S&P 600 Small Cap ETFSPSMiShares Biotechnology ETFIBBDimensional - US Small Cap ETFDFASAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
